Global Anthelmintic Drugs Market Size study, by Drug Class, by Infection Type, by Distribution Channel, and Regional Forecasts 2022-2032

Description

The Global Anthelmintic Drugs Market size was valued at $1.05 billion in 2023 and anticipated to grow at a CAGR of 3.94% from 2024-2032. Anthelmintics are specialized drugs that target and eliminate parasitic worms, or helminths, from the body. These drugs work by either expelling the parasites or disrupting their metabolic processes, leading to their destruction. The increasing prevalence of helminth infections globally is a key driver for market growth. According to the World Health Organization (WHO), soil-transmitted helminth (STH) infections affect an estimated 1.5 billion people, which is approximately 24% of the world's population. These infections are especially prevalent in impoverished communities with limited access to safe water, sanitation, and hygiene, thereby amplifying the demand for anthelmintic drugs.

The growing awareness of preventive measures against helminth infections and the availability of generic drugs significantly contribute to the market expansion. Educational campaigns and public health initiatives play a crucial role in increasing awareness and encouraging proactive measures for the prevention and treatment of parasitic infections. The market dynamics are further influenced by the availability of generic medications, which provide cost-effective alternatives to branded drugs, thereby reducing treatment expenses. However, the affordability of these drugs remains a challenge, particularly in low-income regions where access to healthcare is limited. Moreover, the challenges posed by economic downturns and potential reductions in research funding, the demand for anthelmintic drugs is expected to remain robust due to the high prevalence of parasitic infections and the ongoing need for effective treatments.

The key regions considered for the Global Anthelmintic Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. In 2023, North America dominates the anthelmintic drugs market due to its advanced healthcare infrastructure, high awareness levels, and substantial investment in research and development. The region's strong presence of key pharmaceutical companies, coupled with significant government support for healthcare initiatives, further bolsters its leading position. The prevalence of helminthic infections, particularly in rural and underprivileged areas, drives the demand for effective treatments. Additionally, the increasing adoption of pets and livestock, which are common carriers of parasitic worms, fuels the need for anthelmintic drugs. Stringent regulatory frameworks ensure the availability of high-quality, safe, and effective medications. Furthermore, robust distribution networks and the presence of numerous veterinary and human health clinics facilitate easy access to these drugs. Thus, North America's dominance is attributed to its comprehensive approach to healthcare, encompassing advanced research, widespread awareness, and efficient delivery systems. Furthermore, the Asia-Pacific region is anticipated to be the fastest growing region during the forecast period 2024-2032.

Major market players included in this report are:

GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Bayer AG
Cipla Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
Reese Pharmaceutical Company
Zydus Lifesciences Limited
Cadila Pharmaceuticals
Regulus
John Lee
Mediva
Intas Pharmaceuticals
Mankind Pharma Ltd

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Benzimidazoles
Macrocyclic Lactones
Pyrazinoisoquinolones
Tetrahydropyrimidines
Others

By Infection Type

Cestode Infections
Nematode Infections
Trematode Infections
Mixed Infections

By Distribution Channel

Online Providers
Hospital Pharmacies
Drug Stores and Retail Pharmacies

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Anthelmintic Drugs Market Executive Summary

1.1. Global Anthelmintic Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Infection Type
- 1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Anthelmintic Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Anthelmintic Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Growing Prevalence of Helminth Infections
- 3.1.2. Increasing Awareness for Preventive Measures
- 3.1.3. Availability of Generic Drugs
3.2. Market Challenges
- 3.2.1. Affordability Issues in Low-Income Regions
- 3.2.2. Economic Downturns Impacting Healthcare Budgets
3.3. Market Opportunities
- 3.3.1. Research and Development in Drug Formulations
- 3.3.2. Expansion of Distribution Networks
- 3.3.3. Public Health Initiatives

Chapter 4. Global Anthelmintic Drugs Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Anthelmintic Drugs Market Size & Forecasts by Drug Class 2022-2032

5.1. Segment Dashboard
5.2. Global Anthelmintic Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Benzimidazoles
- 5.2.2. Macrocyclic Lactones
- 5.2.3. Pyrazinoisoquinolones
- 5.2.4. Tetrahydropyrimidines
- 5.2.5. Others

Chapter 6. Global Anthelmintic Drugs Market Size & Forecasts by Infection Type 2022-2032

6.1. Segment Dashboard
6.2. Global Anthelmintic Drugs Market: Infection Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Cestode Infections
- 6.2.2. Nematode Infections
- 6.2.3. Trematode Infections
- 6.2.4. Mixed Infections

Chapter 7. Global Anthelmintic Drugs Market Size & Forecasts by Distribution Channel 2022-2032

7.1. Segment Dashboard
7.2. Global Anthelmintic Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Online Providers
- 7.2.2. Hospital Pharmacies
- 7.2.3. Drug Stores and Retail Pharmacies

Chapter 8. Global Anthelmintic Drugs Market Size & Forecasts by Region 2022-2032

8.1. North America Anthelmintic Drugs Market
- 8.1.1. U.S. Anthelmintic Drugs Market
  - 8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Infection Type breakdown size & forecasts, 2022-2032
  - 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Anthelmintic Drugs Market
  - 8.1.2.1. Drug Class breakdown size & forecasts, 2022-2032
  - 8.1.2.2. Infection Type breakdown size & forecasts, 2022-2032
  - 8.1.2.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2. Europe Anthelmintic Drugs Market
- 8.2.1. U.K. Anthelmintic Drugs Market
- 8.2.2. Germany Anthelmintic Drugs Market
- 8.2.3. France Anthelmintic Drugs Market
- 8.2.4. Spain Anthelmintic Drugs Market
- 8.2.5. Italy Anthelmintic Drugs Market
- 8.2.6. Rest of Europe Anthelmintic Drugs Market
8.3. Asia-Pacific Anthelmintic Drugs Market
- 8.3.1. China Anthelmintic Drugs Market
- 8.3.2. India Anthelmintic Drugs Market
- 8.3.3. Japan Anthelmintic Drugs Market
- 8.3.4. Australia Anthelmintic Drugs Market
- 8.3.5. South Korea Anthelmintic Drugs Market
- 8.3.6. Rest of Asia Pacific Anthelmintic Drugs Market
8.4. Latin America Anthelmintic Drugs Market
- 8.4.1. Brazil Anthelmintic Drugs Market
- 8.4.2. Mexico Anthelmintic Drugs Market
- 8.4.3. Rest of Latin America Anthelmintic Drugs Market
8.5. Middle East & Africa Anthelmintic Drugs Market
- 8.5.1. Saudi Arabia Anthelmintic Drugs Market
- 8.5.2. South Africa Anthelmintic Drugs Market
- 8.5.3. Rest of Middle East & Africa Anthelmintic Drugs Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. GlaxoSmithKline plc
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Johnson & Johnson
- 9.3.3. Merck & Co., Inc.
- 9.3.4. Bayer AG
- 9.3.5. Cipla Ltd.
- 9.3.6. Sun Pharmaceutical Industries Ltd.
- 9.3.7. Teva Pharmaceutical Industries Limited
- 9.3.8. Reese Pharmaceutical Company
- 9.3.9. Zydus Lifesciences Limited
- 9.3.10. Cadila Pharmaceuticals
- 9.3.11. Regulus
- 9.3.12. John Lee
- 9.3.13. Mediva
- 9.3.14. Intas Pharmaceuticals
- 9.3.15. Mankind Pharma Ltd

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes